Medindia
Medindia LOGIN REGISTER
Advertisement

Regenesis Biomedical Announces Additions to Board of Directors

Saturday, August 23, 2008 General News
Advertisement
SCOTTSDALE, Ariz., Aug. 22 Regenesis Biomedical, Inc., amedical technology company that markets the Provant(R) Wound Therapy System,announced today the addition of two members to its Board of Directors. Thetwo new directors are Peter G. Savas, Chairman and CEO of AlseresPharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson andCompany.
Advertisement

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

Peter Savas serves as Chairman and Chief Executive Officer of AlseresPharmaceuticals. Prior to joining Alseres, Peter was Chairman and ChiefExecutive Officer of Aderis Pharmaceuticals, where he completed a $45 millionprivate placement, strengthened the Board of Directors, Scientific AdvisoryBoard and management team and rationalized the company's new productdevelopment partnerships. Peter holds his Bachelor of Arts degree inchemistry from Syracuse University.
Advertisement

Chuck Lunden is a Principal with Bederson and Company, certified publicaccountant consultants who provide financial and accounting services. He hascomprehensive experience in corporate valuation and financial, tax andcorporate management services. His designations include Certified PublicAccountant, Accredited in Business Valuations, Certified Fraud Examiner,Certified Management Accountant, Chartered Life Underwriter, and Fellow of theLife Management Institute. Chuck holds a Bachelor of Science degree ineconomics from the University of Pennsylvania's Wharton School of Business.He is a member of the Board of Directors of HealthCare Data Diagnostics, aMedicare data analysis firm specializing in fraud detection. He is also aMember of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team,"said Virginia Rybski, Acting President of Regenesis. "Regenesis continues todemonstrate impressive revenue growth, and the perspectives of theseindividuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reductionof the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology companyfocused on developing and marketing noninvasive regenerative medicineproducts. Regenesis developed, patented, and now markets the Provant WoundTherapy System. Our customers include health care facilities, acute carehospitals, long-term acute care hospitals, skilled nursing facilities,rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing

http://www.regenesisbiomedical.com 480-970-4970

SOURCE Regenesis Biomedical, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close